Skip to main content

Tekmira Files IND for Hypercholesterolemia Drug with US Regulators


Tekmira Pharmaceuticals said this week that it has filed an investigational new drug application with the US Food and Drug Administration to begin human testing of an siRNA-based treatment for elevated low-density lipoprotein levels.

The drug, ApoB SNALP, targets apolipoprotein B, a protein involved in cholesterol metabolism. Last month, Tekmira President and CEO Mark Murray said that a planned phase I trial for the therapy is expected to enroll around 30 patients with elevated low-density lipoprotein, and will examine the effects of a single administration of the drug on levels of the cholesterol (see RNAi News, 3/26/2009).

The company said this week that it expects to begin the trial before mid-year, in line with previous guidance. Tekmira disclosed last month that development of its other clinical candidate, the cancer drug PLK1 SNALP, had been delayed and that the drug would not likely reach the clinic until next year.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.